KNSA 株価推移チャート
KNSA 収入
Kiniksa Pharmaceuticals International PLC
$77.83
-0.4%
$-0.32
終値： Aug 13, 16:00:00 GMT-4
$79.39
2%
$1.56
アフターマーケット：Aug 13, 20:00:00 GMT-4
戻る
Kiniksa Pharmaceuticals International PLC (KNSA) 収入
最新の利益結果: Q2 '26
報告済み: 2026-07-28
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
KNSAの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Kiniksa Pharmaceuticals International PLC KNSAの前四半期の収益はどうでしたか？
Kiniksa Pharmaceuticals International PLCの収益見積もりはいくらですか？
Kiniksa Pharmaceuticals International PLCの収益品質スコアはどれくらいですか？
Kiniksa Pharmaceuticals International PLCはいつ収益を報告しますか？
Kiniksa Pharmaceuticals International PLCの予想収益はいくらですか？
Kiniksa Pharmaceuticals International PLCは収益予想を上回りましたか？
主要データ
前終値
$78.15
始値
$78.33
当日レンジ
$77.19 - $79.69
52週レンジ
$31.78 - $82.94
取引高
451.3K
平均取引高
778.6K
配当利回り
--
1株当たり利益(TTM)
0.98
時価総額
$6.1B
KNSAとは何ですか？
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
